NCT02213861 - Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Cutaneous T-Cell Lymphoma (CTCL)

Interventions

DRUG

SHAPE

topical gel

Trial Locations (5)

The Ohio State University Wexner Medical Center, Columbus

Northwestern Medical Group, Chicago

The University of Texas MD Anderson Cancer Center, Houston

Stanford Cancer Center, Stanford

Dana-Farber Cancer Institute, Boston